Pritikin ICR

When a cardiologist refers a patient to cardiac rehabilitation, what happens next often determines whether that patient survives another decade or returns to the hospital within a year. Standard cardiac rehabilitation programs have historically struggled with low patient engagement, fragmented protocols, and limited outcomes data — leaving a dangerous gap between life-saving procedures and sustainable lifestyle transformation. Pritikin Intensive Cardiac Rehabilitation was built to close that gap. Founded on the science pioneered by Nathan Pritikin, who opened the original Pritikin Longevity Center in California in 1975, the program represents nearly five decades of evidence-based cardiovascular lifestyle medicine compressed into a structured, replicable franchise model for healthcare providers. Pritikin ICR began licensing its program to hospitals and outpatient facilities in 2013, and the franchise is headquartered in Clayton, Missouri. The organization operates under Pritikin ICR, LLC, with Terry Rogers serving as President, John Cody as Chief Operating Officer, and Jared Sieling as Chief Technology Officer. From a single pilot location at the Heart Care Institute in Creve Coeur, Missouri in 2013, the Pritikin ICR franchise has scaled to 146 licensed healthcare provider locations across the United States as of 2025, with the company approaching 300 licensed locations nationwide as of April 2025. For franchise investors and healthcare executives evaluating this opportunity, the brand sits at the intersection of two powerful trends: the clinical imperative to reduce cardiovascular readmissions and the Medicare-reimbursed Intensive Cardiac Rehabilitation designation that creates a unique, government-backed revenue mechanism for participating providers. This is independent analysis, not marketing copy, and the data presented here reflects the most comprehensive compilation of Pritikin ICR franchise intelligence available in one place.

The total addressable market for cardiac rehabilitation services in the United States is enormous and growing. Cardiovascular disease remains the leading cause of death in America, accounting for approximately one in every five deaths, and over 800,000 Americans suffer a heart attack each year. Medicare coverage for cardiac rehabilitation is well established, but the more clinically intensive ICR designation — which Pritikin holds — commands reimbursement for up to 72 sessions per patient compared to the 36 sessions covered under standard cardiac rehab, effectively doubling the revenue potential per patient episode for participating providers. The U.S. cardiac rehabilitation market is projected to grow at a compound annual growth rate exceeding 6% through the late 2020s, driven by three concurrent forces: an aging Baby Boomer population now entering peak cardiovascular risk years, rising rates of Type 2 diabetes and metabolic syndrome that feed into cardiovascular event rates, and growing insurer and hospital system pressure to reduce 30-day readmission penalties under value-based care frameworks. The secular tailwind behind Pritikin ICR is not discretionary consumer spending — it is demographic inevitability combined with federal reimbursement policy. Only three programs in the United States have received the CMS designation as Intensive Cardiac Rehabilitation programs, which creates a structurally limited competitive landscape rather than a fragmented, commoditized one. The Pritikin ICR franchise therefore does not compete on price or brand awareness in the traditional consumer franchise sense — it competes on clinical outcomes, provider adoption speed, and the depth of its lifestyle change curriculum, which draws from over 45 years of peer-reviewed research originating with Nathan Pritikin's foundational work beginning in 1975.

Understanding the Pritikin ICR franchise cost requires navigating some data variation across sources that prospective licensees must verify directly in the current Franchise Disclosure Document. The franchise fee structure is reported differently across research databases: FranchiseGrade's 2024 FDD data and multiple aggregators including Vetted Biz indicate a franchise fee of $0, while FranDesk reports a range of $20,088 to $21,788. Prospective franchisees should treat these discrepancies as a prompt to request the current FDD directly from the franchisor and confirm figures with a franchise attorney before proceeding. The total Pritikin ICR franchise investment is similarly reported across a range depending on the source and year: the 2024 FDD data compiled by FranchiseGrade puts the total investment range at $5,709 to $46,709, while SharpSheets' 2025 data estimates the range at $6,000 to $52,000, and Vetted Biz reports $5,730 to $51,980. FranDesk presents a higher range of $25,864 to $75,526. The investment spread within any given source reflects variables including facility setup requirements, program materials, equipment needs, whether space is leased or already owned by the healthcare provider, and the scale of the initial operational buildout. Compared to the average total investment for a traditional consumer-facing franchise, which commonly ranges from $250,000 to over $1 million once real estate, equipment, and working capital are factored in, the Pritikin ICR franchise investment range is strikingly accessible — this is a program that grafts onto existing healthcare infrastructure rather than requiring greenfield construction. The royalty fee is reported at 6% of gross revenue by SharpSheets' 2025 data, though FranchiseGrade's 2024 FDD data reports an 18.5% royalty, a significant discrepancy that makes direct FDD review critical. A 2% marketing fee of gross revenue is cited by SharpSheets. Working capital requirements are reported by FranchiseGrade at $0 to $26,000, with Vetted Biz citing a minimum cash requirement of $5,000. The low capital threshold makes this an unusually accessible franchise opportunity for hospital systems, outpatient cardiac programs, and physician group practices that already possess the physical infrastructure.

The operating model of Pritikin ICR is fundamentally different from a consumer franchise where the franchisee builds a new storefront and attracts customers from a local market. In this model, the franchisee is a healthcare provider — typically a hospital system, hospital-affiliated outpatient center, or physician-led cardiac practice — that licenses the Pritikin ICR curriculum, clinical protocols, staff training system, and brand to operate an ICR program within their existing facility. The franchisor provides a comprehensive training program for clinical staff, equipping dietitians, exercise physiologists, and cardiac nurses with the specific Pritikin lifestyle medicine methodology that forms the foundation of the program. Ongoing support includes access to Pritikin's proprietary technology platform managed by Chief Technology Officer Jared Sieling, regular field support from the corporate team led by COO John Cody, and marketing resources designed to help provider locations generate physician referrals and patient enrollment. The staffing model is embedded within the healthcare provider's existing clinical workforce rather than requiring the franchisee to recruit and manage a standalone team from scratch, which reduces one of the most significant operational friction points in franchise launches. The first franchised site — the Heart Care Institute in Creve Coeur, Missouri — has since administered over 101,000 ICR sessions, demonstrating the scale achievable at a single location when the model is properly implemented and the referral pipeline is active. The HCI has seen nearly 70% of participants attend at least 61 sessions, graduated 2,500 ICR patients, and maintained a 46% education completion rate, which are remarkable engagement metrics for a medically supervised behavioral change program. Territory structure and multi-unit dynamics differ from traditional franchising given the healthcare provider context, but the 2024 FDD data confirms operations across 29 states, with the South representing the largest regional concentration at 52 franchise locations.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Pritikin ICR, which means prospective franchisee-operators cannot access audited average or median revenue figures directly from the franchisor's disclosure materials. This is a meaningful data gap that investors and healthcare executives should weigh carefully during due diligence, as it limits the ability to benchmark expected unit-level economics against a disclosed franchisor standard. That said, several publicly available data signals inform a reasonable analytical framework. Pritikin ICR's estimated aggregate annual revenue is approximately $15.3 million, with an estimated revenue per employee of $243,000 — the latter figure suggesting a lean, high-productivity staffing model consistent with a medically supervised outpatient setting. The program has treated more than 65,000 patients as of February 2023, and in the twelve months leading up to April 2025, Pritikin ICR provider locations collectively treated nearly 40,000 patients in a single year — a figure that implies significant acceleration in patient volume as the network has scaled. The ICR Medicare reimbursement structure, which allows up to 72 covered sessions per patient at reimbursement rates that typically range from $75 to over $100 per session depending on the CMS rate schedule and setting, creates a revenue ceiling per patient episode that can approach $5,000 to $7,000 in gross billings before any cost-sharing. For a provider location that enrolls even 100 patients per year at an average attendance near the 61-session threshold demonstrated at the Heart Care Institute, the gross revenue contribution from the ICR program alone represents a material and recurring clinical revenue stream. Prospective franchisees are strongly encouraged to model revenue scenarios using current CMS reimbursement schedules, their local patient referral capacity, and the HCI's documented engagement benchmarks as a reference case, while conducting independent discussions with existing Pritikin ICR franchisee locations to gather direct operational and financial insight.

The growth trajectory of the Pritikin ICR franchise is among the most compelling quantitative signals in its investment profile. Starting from zero licensed locations before 2013, the brand reached 5 open locations by May 2015, crossed 30 licensed hospital facilities by July 2017, surpassed 100 locations by February 2023, and reached 111 franchised locations according to the 2024 FDD data. By 2025, the network had grown to 146 licensed provider locations, and the company described itself as approaching 300 licensed locations nationwide as of April 2025. This trajectory — from 5 locations in 2015 to approaching 300 in 2025 — represents a roughly 60-fold increase in network scale over a decade, a growth rate that significantly outpaces the median franchise system expansion across the broader industry. The competitive moat protecting this growth is multi-layered. First, the CMS Intensive Cardiac Rehabilitation designation held by Pritikin is not awarded broadly — the regulatory approval process creates a durable barrier to entry that generic cardiac rehabilitation programs cannot replicate simply by copying the format. Second, nearly five decades of published clinical research supporting the Pritikin dietary and exercise methodology gives the program a scientific credibility architecture that a startup competitor cannot acquire quickly. Third, the technology infrastructure built under CTO Jared Sieling provides provider locations with reporting, patient tracking, and outcomes documentation capabilities that support both clinical quality management and payer contracting. Fourth, the network effect of a growing referral community — cardiologists who have seen their patients succeed in Pritikin ICR programs become repeat referral sources — strengthens as the network expands into more markets and hospital systems. The South's dominance at 52 franchise locations suggests regional concentration that may both reflect favorable demographics and signal where corporate growth resources have been directed, with 29 states currently covered creating significant geographic whitespace for continued expansion.

The ideal Pritikin ICR franchise candidate is fundamentally different from the profile of a typical retail or food-service franchisee. This opportunity is designed specifically for healthcare providers — hospital systems, integrated health networks, outpatient cardiac rehabilitation programs, and physician group practices with access to the cardiac patient population and existing clinical space. Prior experience in healthcare administration, clinical operations, or cardiovascular medicine is not merely advantageous but essentially prerequisite to operating this model effectively, since the program must be embedded within a functioning clinical workflow and staffed by credentialed healthcare professionals. The 2024 FDD confirms that all 111 franchised locations at the time of filing were operating within the United States, across 29 states, with the South accounting for the largest share at 52 locations — suggesting that population density, cardiovascular disease prevalence rates, and perhaps regional Medicare utilization patterns all influence geographic performance. Available territories span the significant portion of the country where Pritikin ICR has not yet established a licensed provider, including major healthcare markets in the Midwest, Northeast, and Pacific regions. The franchise agreement structure, renewal terms, and transfer conditions are detailed in the FDD, which prospective licensees should review with a qualified franchise attorney given the discrepancies in publicly reported fee data across research databases. The timeline from initial inquiry to program launch can vary based on the complexity of the provider's existing facility and staff training requirements, but given the absence of a real estate or construction component in most implementations, the operational buildout is substantially faster than a traditional franchise concept.

The investment thesis for the Pritikin ICR franchise opportunity rests on three converging pillars: a government-reimbursed clinical service with demonstrated patient demand, a scientifically credentialed program with nearly 50 years of published outcomes data, and a franchise network that has demonstrated the ability to scale from 5 locations in 2015 to approaching 300 in 2025 without requiring the capital intensity of consumer-facing franchise formats. The low total investment range of approximately $6,000 to $52,000 per the most recent publicly available data makes this among the most capital-efficient healthcare franchise opportunities in the market, particularly relative to the potential recurring revenue from Medicare ICR reimbursements over a multiyear patient population. The absence of Item 19 disclosure remains a genuine due diligence consideration, and the discrepancies in reported royalty rates between 6% and 18.5% across different research sources underscore the importance of reviewing the current FDD directly rather than relying on third-party aggregators alone. For any healthcare executive, hospital administrator, or physician group considering expanding their cardiovascular service line with a differentiated, clinically validated, and Medicare-supported program, the Pritikin ICR franchise represents a category that merits serious investigation. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools to help investors evaluate this opportunity against alternative franchise investments across the healthcare and wellness landscape with full analytical rigor. Explore the complete Pritikin ICR franchise profile on PeerSense to access the full suite of independent franchise intelligence data.